Investors

PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary Aldeyra Therapeutics to Present Novel Data on the Anti-Inflammatory Mechanism and Activity of ADX-102 at the World Congress on Inflammation 2017 Annual Meeting
LEXINGTON, Mass. , June 19, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc.  (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, today announced that novel data on the
View HTML
Toggle Summary Aldeyra Therapeutics Announces Results from Allergic Conjunctivitis Phase 2b Clinical Trial and Plans for Phase 3 Clinical Testing
One-Point Reduction vs. Control Component of Primary Endpoint Not Met but 0.5% ADX-102 Statistically Superior to Control and Demonstrates Late-Phase Anti-Inflammatory Activity Differentiated from Standard of Care Clear Evidence of ADX-102 Dose Response Phase 3 Clinical Testing Planned Following End of Phase 2 Discussion with Regulatory Authorities in the Second Half of 2017
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Results from Allergic Conjunctivitis Phase 2b Clinical Trial
LEXINGTON, Mass. , June 13, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehyde toxicity, announced they will host a conference call
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Dry Eye Disease Phase 2a Clinical Trial
LEXINGTON, Mass. , June 6, 2017 /PRNewswire/ --  Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced that it has enrolled the first patient
View HTML
Toggle Summary Aldeyra Therapeutics Presents Noninfectious Anterior Uveitis Phase 2 Clinical Trial Data at the Association for Research in Vision and Ophthalmology 2017 Annual Meeting
Data Demonstrate ADX-102 Activity Comparable to Topical Ocular Corticosteroids But Without Known Corticosteroid Side Effects
View HTML
Toggle Summary Aldeyra Therapeutics Provides Corporate Update and Announces First Quarter 2017 Financial Results
Significant Platform Advancement Across Four Clinical ProgramsDetails Provided on 2017 and 2018 Catalysts
View HTML
Toggle Summary Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide Corporate Update and First Quarter 2017 Financial Results
LEXINGTON, MA -- (Marketwired) -- 05/08/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotechnology company devoted to treating inflammation, inborn errors of metabolism, and other diseases related to aldehydes, today announced it will provide a corporate update and
View HTML
Toggle Summary Aldeyra Therapeutics Announces First Patient Enrolled in Noninfectious Anterior Uveitis Phase 3 Clinical Trial
LEXINGTON, MA -- (Marketwired) -- 04/27/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated
View HTML
Toggle Summary Aldeyra Therapeutics, Inc. Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-102 in Sjögren-Larsson Syndrome
LEXINGTON, MA -- (Marketwired) -- 04/20/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a clinical-stage biotech company devoted to treating diseases thought to be related to endogenous aldehydes, a naturally occurring class of pro-inflammatory and toxic molecules, today announced that
View HTML
Toggle Summary Aldeyra Therapeutics, Inc. Announces Last Patient Dosed in Allergic Conjunctivitis Phase 2b Clinical Trial
LEXINGTON, MA -- (Marketwired) -- 04/18/17 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused primarily on the development of new products for inflammation, inborn errors of metabolism, and other diseases that are thought to be related to endogenously generated
View HTML